Heather Renee Williams, MD

Research Program: Cancer Therapeutics Faculty Rank: Assistant Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: OB & GYN Gynecologic Oncology

Cancer Research Interest

• Disease Site Focus: Gynecology
• Research Focus Area: Prevention, Health Disparities, Treatment, Diagnosis/ Prognosis
• Type of Research: Clinical
• Research Keywords: I direct the clinical trial portfolio for gyn onc
• Research Interest Statement: I am currently the Clinical Trial Director for the Gyn Onc Division and serve as the PI for several trials sponsored by NRG and GOG partners. I am the site PI for GOG Partners. Since coming to this role in 2022, I have been focused on expanding our portfolio and increasing our trial enrollment. I have an interest in health disparities and their impact on cancer development and prognosis. I am also interested in support services for patients undergoing treatments and issues related to survivorship. Our site is participating in a national trial evaluating support for black women receiving treatment for endometrial cancer and we have exceeded our original enrollment goal.

Contact Information

• Email Address: HRWILLIAMS2@UAMS.EDU
• Profiles Research Networking Software: View Profile

Open Clinical Trials

• “A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy” (NCT06486441)
• “NRG CC008, A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer AmongBRCA1 Carriers [SOROCk]” (NCT04251052)
• “A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients with p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma” (NCT05611931)
• “A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status” (NCT05548296)
• “NRG-GY026: A Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) or pertuzumab trastuzumab and hyaluronidase-zzfx (PHESGO) in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma” (NCT05256225)
• “The Social Interventions for Support during Treatment for Endometrial Cancer and Recurrence (SISTER) Study” (NCT04930159)
• “NRG-GY022 Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin ” (NCT03997370)

Recent Publications

• Nichols M, Kesaria A, Spencer HJ, [et al., including Williams HR]. Opioid Use in Patients With Cervical Cancer at a Tertiary Academic Medical Center. Anticancer research. 2024 44(1):151-155. PMID: 38160002.
• Hamza MA, Quick CM, Williams HR, [et al.]. HPV-associated Vulvar Intraepithelial Carcinoma With Sebaceous Differentiation: Report of 2 Cases. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 2022. PMID: 36383010.
• Wang YJ, Williams HR, Brzezinska BN, [et al.]. Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature. Gynecologic oncology reports. 2021 35:100701. PMID: 33537390. PMCID: PMC7843391.